NCT07321678CompletedPhase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 5 Jan 2026
- Start date
- 22 Jan 2026
- Primary completion date
- 10 Aug 2026
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Diseases
- Type 2 diabetes
- NCT number
- NCT07321678
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 100
- From 22 Jan 2026 to the primary completion date, 10 Aug 2026
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have any prior diagnosis of type 1 diabetes mellitus (T1DM), or rare forms of diabetes mellitus
Other illness
- Have poorly controlled hypertension
- Have acute or chronic hepatitis and pancreatitis
- Have evidence of a significant active and uncontrolled medical condition
Other
- Have had more than 1 episode of severe hypoglycemia
Who the study is looking for
- Have Type 2 Diabetes (T2D)
- Have HbA1c ≥7.0% to ≤10.5% as determined by the central laboratory at screening.
- Stable body weight (less than 5% self-reported change within the previous 3 months).
- Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Decatur | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Denver | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Riverside | United States | Unknown status |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| - Coordinator of this site? Confirm its status | San Jose | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Springfield | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.